Overview

Micro Glucagon During Exercise in Type 1 Diabetes

Status:
Not yet recruiting
Trial end date:
2021-06-01
Target enrollment:
0
Participant gender:
All
Summary
This proof-of-principle study to assess effects of different doses (mini and micro) of subcutaneous glucagon analog Dasiglucagon (Zealand Pharma, Copenhagen, Denmark) on the change in blood glucose concentration during moderate-intensity exercise in people with T1D.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Hospital Inselspital, Berne
Treatments:
Glucagon
Glucagon-Like Peptide 1
Criteria
Inclusion Criteria:

- T1D for >1 year

- Male aged 18-45 years old

- HbA1c <8.0% (64 mmol/mol) based on analysis from the central laboratory unit of Bern
University Hospital

- Regular physical activity (defined as meeting 150 min moderate-intensity exercise per
week)

- Using either continuous subcutaneous insulin infusion or multiple daily injections

- Written informed consent

Exclusion Criteria:

- Physical or psychological disease likely to interfere with the normal conduct of the
study and interpretation of the results as judged by the investigator

- Current treatment with drugs known to interfere with metabolism e.g. systemic
corticosteroids, statins, SGLT2 inhibitors, GLP1 agonists

- Relevant diabetic complications as judged by the investigator

- Body mass index 30 kg/m2

- Uncontrolled hypertension (>180/100 mmHg)